Not an anti-aging play? Altos’ top scientist says they can prevent aging in 20 years
The narrative at the highly secretive and well-funded Altos, brought together by Rick Klausner, is that it’s not an anti-aging company. Klausner made that clear when he spoke with Endpoints earlier this year: “We do not view this as either an aging company or a longevity company.”
Rather, the goal was to build up a team of scientific heavyweights and top industry leaders, pair it with beyond-substantial levels of funding with a capital B — and then set the company loose into the depths of cellular rejuvenation biology.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.